Because NKX2–1 copy number gains also have been identified in LUAD and NEPC, we investigated whether NKX2–1 associated elevation of serine/glycine synthesis enzyme expression is uniformly observed across all cancer types. This evidence concerns the gene NKX2-1 and cancer.